Poland· PL-100312676
Alortia
A losartan und amlodipin product containing losartanum kalicum + amlodipinum, registered in Poland by Krka, d.d., Novo mesto.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Losartanum kalicum + Amlodipinum
- Manufacturer
- Krka, d.d., Novo mesto
- Country
- Poland (PL)
- ATC code
- C09DB06
- ATC class
- Losartan und Amlodipin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 7
3 priced- gtin0590999110572330 szt.PLN 15.93
- gtin0590999110574760 szt.PLN 30.8
- gtin0590999110576190 szt.PLN 44.89
- gtin05909991105709
- gtin05909991105730
- gtin05909991105754
- gtin05909991191382
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for losartan und amlodipin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Losartan und amlodipin · interactions on record
8 records
8 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Losartan und amlodipin in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Bulgaria · Тенлорис
- Germany · Losamlo
- Hungary · Losartan/Amlodipin Krka, Tenloris
- Latvia · Tenloris
- Portugal · Blocan
- Slovenia · Alortya
- Slovakia · Tenloris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6b70b22-5d6c-4ebc-a4c9-0518afc9b985 GET /v1/drugs/c6b70b22-5d6c-4ebc-a4c9-0518afc9b985?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 10 mg",
"packaging": "05909991105709 ¦ Rp ¦ 90092\n28 tabl.\n05909991105723 ¦ Rp ¦ 90093\n30 tabl.\n05909991105730 ¦ Rp ¦ 90095\n56 tabl.\n05909991105747 ¦ Rp ¦ 90096\n60 tabl.\n05909991105754 ¦ Rp ¦ 90097\n84 tabl.\n05909991105761 ¦ Rp ¦ 90098\n90 tabl.\n05909991191382 ¦ Rp ¦ 104189\n10 tabl.",
"substance": "Losartanum kalicum 50 mg + Amlodipinum 10 mg",
"common_name": "Losartanum kalicum + Amlodipinum",
"pl_product_id": "100312676",
"pozwolenie_nr": "21711",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about losartan und amlodipin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.